New hope for High-Risk pregnancies: drug may prevent miscarriage and early delivery

NCT ID NCT03152058

First seen Apr 07, 2026 · Last updated Apr 30, 2026 · Updated 6 times

Summary

This study tests whether adding certolizumab to standard treatment (heparin and low-dose aspirin) can prevent pregnancy complications like fetal death or early delivery in pregnant women with antiphospholipid syndrome (APS) and lupus anticoagulant. About 55 women will receive the drug, and their outcomes will be compared to a previous study group. The goal is to improve the chances of a healthy pregnancy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY COMPLICATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital for Special Surgery

    RECRUITING

    New York, New York, 10021, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • TRIO Advancing Reproductive Care

    RECRUITING

    Toronto, Ontario, M5G 2K4, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Utah

    RECRUITING

    Salt Lake City, Utah, 84132, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.